MCID: CTN015
MIFTS: 56

Cutaneous T Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous T Cell Lymphoma

MalaCards integrated aliases for Cutaneous T Cell Lymphoma:

Name: Cutaneous T Cell Lymphoma 12 15
Cutaneous T-Cell Lymphoma 12 77 54 17
Lymphoma, T-Cell, Cutaneous 45 74
Lymphoma T-Cell Cutaneous 56
Ctcl 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0060061
MeSH 45 D016410
UMLS 74 C0079773

Summaries for Cutaneous T Cell Lymphoma

NIH Rare Diseases : 54 Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by an abnormal accumulation of cancerous T-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. CTCLs belong to a larger group of disorders known asnon-Hodgkin's lymphomas. The most common types are mycosis fungoides and Sézary syndrome. In some cases, cancerous T-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in life-threatening complications. The specific signs and symptoms vary from person to person. The exact cause of these conditions is unknown.

MalaCards based summary : Cutaneous T Cell Lymphoma, also known as cutaneous t-cell lymphoma, is related to sezary's disease and adult t-cell leukemia. An important gene associated with Cutaneous T Cell Lymphoma is CTAGE1 (Cutaneous T Cell Lymphoma-Associated Antigen 1), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Bexarotene and Methoxsalen have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin's lymphoma that has material basis in a mutation of T cells.

Wikipedia : 77 Cutaneous T cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the... more...

Related Diseases for Cutaneous T Cell Lymphoma

Diseases in the Cutaneous T Cell Lymphoma family:

Primary Cutaneous Gamma/delta-Positive T-Cell Lymphoma

Diseases related to Cutaneous T Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
# Related Disease Score Top Affiliating Genes
1 sezary's disease 31.1 CCR10 CCR4 IFNA1 IFNG IL15 IL2
2 adult t-cell leukemia 30.7 IL2 IL2RA TNFRSF8
3 graft-versus-host disease 30.6 GZMB IFNG IL2
4 mycosis fungoides 30.4 CCR10 CCR4 GZMB IFNA1 IL15 IL2
5 chronic graft versus host disease 30.4 IFNG IL2RA
6 autoimmune disease 30.2 IFNA1 IFNG IL2 IL2RA
7 hairy cell leukemia 30.2 IFNA1 IL2 IL2RA
8 acquired immunodeficiency syndrome 30.2 IFNA1 IFNG IL2 IL2RA
9 tropical spastic paraparesis 30.1 IFNG IL2 IL2RA
10 human immunodeficiency virus infectious disease 30.1 IFNA1 IFNG IL2 IL7
11 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.0 IFNG IL2 IL2RA
12 fixed drug eruption 30.0 CCR4 IFNG IL2
13 multiple sclerosis 30.0 IFNA1 IFNG IL2 IL2RA
14 lymphomatoid papulosis 30.0 GZMB TIA1
15 measles 30.0 IFNA1 IFNG IL2
16 hemophagocytic lymphohistiocytosis 30.0 GZMB IFNG IL2RA
17 lymphopenia 29.8 IFNG IL2 IL2RA IL7
18 lichen sclerosus et atrophicus 29.7 GZMB TIA1
19 human immunodeficiency virus type 1 29.7 IFNA1 IFNG IL2 IL7
20 lymphoma, non-hodgkin, familial 29.7 GZMB IL15 IL2 IL2RA TNFRSF8
21 panniculitis 29.7 GZMB IFNG TIA1
22 composite lymphoma 29.5 GZMB TIA1
23 peripheral t-cell lymphoma 29.3 CCR4 GZMB IL2 TIA1 TNFRSF8
24 hydroa vacciniforme-like lymphoma 11.9
25 parapsoriasis 11.6
26 granulomatous slack skin disease 11.6
27 lymphoma 11.5
28 leukemia 10.6
29 dermatitis 10.5
30 t-cell leukemia 10.4
31 pelvic lipomatosis 10.4 IL15 IL2
32 dermatitis, atopic 10.4
33 psoriasis 10.4
34 variola major 10.4 IFNG IL2
35 lymphocytic leukemia 10.3
36 hyperlucent lung 10.3 IFNG IL2RA
37 large granular lymphocyte leukemia 10.3 IFNG IL2RA
38 murray valley encephalitis 10.3 IFNA1 IL2
39 berylliosis 10.3 IFNG IL2
40 refractory celiac disease 10.3 IFNG IL15
41 leukemia, chronic lymphocytic 2 10.3
42 leukemia, chronic lymphocytic 10.3
43 leukemia, b-cell, chronic 10.3
44 b-cell growth factor 10.3 IFNG IL7
45 hydroa vacciniforme 10.3
46 hypersensitivity reaction type iv disease 10.2 IFNA1 IFNG IL2
47 intermediate uveitis 10.2 IFNG IL2 IL2RA
48 posterior uveitis 10.2 IFNG IL2 IL2RA
49 vernal conjunctivitis 10.2 IFNG IL2 IL2RA
50 jak3-deficient severe combined immunodeficiency 10.2 IL15 IL2

Graphical network of the top 20 diseases related to Cutaneous T Cell Lymphoma:



Diseases related to Cutaneous T Cell Lymphoma

Symptoms & Phenotypes for Cutaneous T Cell Lymphoma

MGI Mouse Phenotypes related to Cutaneous T Cell Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR10 CCR4 HSD17B11 IFNG IL15 IL2
2 immune system MP:0005387 9.32 CCR10 CCR4 HSD17B11 IFNG IL15 IL2

Drugs & Therapeutics for Cutaneous T Cell Lymphoma

Drugs for Cutaneous T Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 436)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 153559-49-0 82146
2
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-81-7 4114
3
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
5
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 173146-27-5
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 59-30-3 6037
7 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable
8 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Vitamin B9 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
15 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Folate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
21 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Interferon alpha-2 Phase 4,Phase 2,Not Applicable
23 Interferon-alpha Phase 4,Phase 2,Not Applicable
24 interferons Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Clorazepate Dipotassium Phase 4
26
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
27
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
28 Orange Approved Phase 3
29
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
30
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
31
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
32
Ofloxacin Approved Phase 3 82419-36-1 4583
33
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
34
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
35
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
36
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
37
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
38
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
39
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
40
Lenalidomide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
41
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 23214-92-8 31703
42
Panobinostat Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 404950-80-7 6918837
43
Iron Approved, Experimental Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
44
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
46
Vancomycin Approved Phase 3 1404-90-6 14969 441141
47
Piperacillin Approved Phase 3 66258-76-2 43672
48
Tazobactam Approved Phase 3 89786-04-9 123630
49
Dalteparin Approved Phase 3 9005-49-6
50
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 46507594 772

Interventional clinical trials:

(show top 50) (show all 499)
# Name Status NCT ID Phase Drugs
1 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
2 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
3 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
4 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
5 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
6 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
7 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
8 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
9 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
10 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
11 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
12 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
13 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
14 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
15 PUVA Maintenance Therapy in Mycosis Fungoides Completed NCT01686594 Phase 3 8-methoxypsoralen
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
18 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
19 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
22 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
23 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
24 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
26 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
27 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
28 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
29 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
30 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
31 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
32 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
33 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
34 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
35 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
36 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
37 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
38 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
39 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Recruiting NCT01871727 Phase 3 E7777 9 mcg/kg
40 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
41 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Active, not recruiting NCT01728805 Phase 3 Vorinostat
42 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
43 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
44 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
45 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
46 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
47 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
48 Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Unknown status NCT01132989 Phase 2 Lenalidomide
49 Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma Unknown status NCT02213861 Phase 2 SHAPE
50 Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) Unknown status NCT02546440 Phase 2 dimethylfumarate

Search NIH Clinical Center for Cutaneous T Cell Lymphoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: lymphoma, t-cell, cutaneous

Genetic Tests for Cutaneous T Cell Lymphoma

Anatomical Context for Cutaneous T Cell Lymphoma

MalaCards organs/tissues related to Cutaneous T Cell Lymphoma:

42
T Cells, Skin, Bone, Bone Marrow, B Cells, Liver, Lymph Node

Publications for Cutaneous T Cell Lymphoma

Articles related to Cutaneous T Cell Lymphoma:

(show top 50) (show all 1753)
# Title Authors Year
1
Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). ( 31106143 )
2019
2
Early changes in gene expression of the entire pathological process in Cutaneous T-cell lymphoma. ( 31106473 )
2019
3
Iron Deficiency Anemia in Patients Undergoing Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma. ( 29955854 )
2019
4
Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome. ( 30180750 )
2019
5
Cutavirus DNA in Malignant and Nonmalignant Skin of Cutaneous T-Cell Lymphoma and Organ Transplant Patients but Not of Healthy Adults. ( 30239652 )
2019
6
IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model. ( 30277131 )
2019
7
Secukinumab for treatment of psoriasis: does secukinumab precipitate or promote the presentation of cutaneous T-cell lymphoma? ( 30284290 )
2019
8
Association of insurance status with survival in patients with cutaneous T-cell lymphoma. ( 30326769 )
2019
9
Generalized fixed drug eruption mimicking CD8+ cutaneous T-cell lymphoma in HIV. ( 30328131 )
2019
10
Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification. ( 30328260 )
2019
11
High-throughput sequencing of the T-cell receptor β chain gene distinguishes 2 subgroups of cutaneous T-cell lymphoma. ( 30365996 )
2019
12
Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. ( 30430444 )
2019
13
Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. ( 30525759 )
2019
14
Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015. ( 30591466 )
2019
15
Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma. ( 30597607 )
2019
16
Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument. ( 30617041 )
2019
17
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. ( 30626755 )
2019
18
Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture? ( 30632848 )
2019
19
MicroRNAs in Cutaneous T-Cell Lymphoma: The Future of Therapy. ( 30686578 )
2019
20
Does continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma? A retrospective case series review. ( 30712496 )
2019
21
Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression. ( 30718356 )
2019
22
Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma. ( 30745139 )
2019
23
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. ( 30799938 )
2019
24
Clonotypic diversity of the T-cell receptor corroborates the immature precursor origin of cutaneous T-cell lymphoma. ( 30808775 )
2019
25
Emerging insights on the biology and treatment of cutaneous T-cell lymphoma. ( 30818956 )
2019
26
Systemic therapy of cutaneous T-cell lymphoma (CTCL). ( 30818958 )
2019
27
Synthesis and Investigation of Therapeutic Potential of Isoform Specific HDAC8 Inhibitors for The Treatment of Cutaneous T Cell Lymphoma. ( 30836926 )
2019
28
Developing BET-ter treatments for cutaneous T-cell lymphoma. ( 30863486 )
2019
29
Key Role of Reactive Oxygen Species (ROS) in Indirubin Derivative-Induced Cell Death in Cutaneous T-Cell Lymphoma Cells. ( 30866411 )
2019
30
Preclinical Targeting of MicroRNA-214 in Cutaneous T-cell Lymphoma (CTCL). ( 30876800 )
2019
31
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells. ( 30885250 )
2019
32
Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. ( 30892982 )
2019
33
Silent T-cell receptor cutaneous T-cell lymphoma associated to a clonal plasma cell proliferation. ( 30915203 )
2019
34
Health-related quality of life and economic implications of cutaneous T-cell lymphoma. ( 30920642 )
2019
35
Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma. ( 30943788 )
2019
36
Angiogenesis in cutaneous T-cell lymphoma - proteomic approaches. ( 30944599 )
2019
37
Harnessing the synergistic potential of biologically targeted therapies in cutaneous T-cell lymphoma. ( 30956764 )
2019
38
Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. ( 30962713 )
2019
39
Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing. ( 30967393 )
2019
40
Single-cell lymphocyte heterogeneity in advanced Cutaneous T-Cell Lymphoma skin tumors. ( 31010835 )
2019
41
CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma. ( 31028199 )
2019
42
Skin Directed Therapy in Cutaneous T-Cell Lymphoma. ( 31032224 )
2019
43
Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection. ( 31046767 )
2019
44
Low Drosha protein expression in cutaneous T cell lymphoma is associated with worse disease outcome. ( 31055868 )
2019
45
CAR-Based Approaches to Cutaneous T-Cell Lymphoma. ( 31058076 )
2019
46
Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201). ( 31090237 )
2019
47
Hydroa Vacciniforme-Like Cutaneous T-Cell Lymphoma in an Adult Presenting With Facial Edema and Recurrent Oral Ulceration. ( 29473835 )
2018
48
Methotrexate-Associated B-Cell Lymphoproliferative Disease in a Patient With Cutaneous T-Cell Lymphoma. ( 29490369 )
2018
49
Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm. ( 29505472 )
2018
50
Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma. ( 29511289 )
2018

Variations for Cutaneous T Cell Lymphoma

Cosmic variations for Cutaneous T Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,cutaneous T cell lymphoma c.38G>A p.G13D 12:25245347-25245347 0

Copy number variations for Cutaneous T Cell Lymphoma from CNVD:

7 (show all 49)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21732 1 16100000 20300000 Amplification Cutaneous T-cell lymphoma
2 25426 1 189000000 192100000 Deletion Cutaneous T-cell lymphoma
3 38869 10 105700000 111800000 Deletion Cutaneous T-cell lymphoma
4 39996 10 12300000 17300000 Deletion Cutaneous T-cell lymphoma
5 41377 10 17300000 19900000 Amplification Cutaneous T-cell lymphoma
6 42285 10 31400000 34500000 Deletion Cutaneous T-cell lymphoma
7 47113 10 89600000 92900000 Deletion PTEN Cutaneous T-cell lymphoma
8 61605 12 10000000 12600000 Deletion ETV6 Cutaneous T-cell lymphoma
9 71417 12 69800000 74100000 Deletion Cutaneous T-cell lymphoma
10 77639 13 46200000 48900000 Deletion RB1 Cutaneous T-cell lymphoma
11 83022 14 19100000 23600000 Deletion NDRG2 Cutaneous T-cell lymphoma
12 83023 14 19100000 23600000 Deletion ZNF219 Cutaneous T-cell lymphoma
13 97437 16 10300000 12500000 Deletion Cutaneous T-cell lymphoma
14 98274 16 16700000 20500000 Deletion Cutaneous T-cell lymphoma
15 107006 17 11200000 15900000 Deletion MAP2K4 Cutaneous T-cell lymphoma
16 108845 17 23200000 28800000 Amplification DHRS13 Cutaneous T-cell lymphoma
17 108846 17 23200000 28800000 Amplification ERAL1 Cutaneous T-cell lymphoma
18 108847 17 23200000 28800000 Amplification FLOT2 Cutaneous T-cell lymphoma
19 108848 17 23200000 28800000 Amplification PHF12 Cutaneous T-cell lymphoma
20 112029 17 37800000 41900000 Amplification Cutaneous T-cell lymphoma
21 116538 17 6800000 11200000 Deletion TP53 Cutaneous T-cell lymphoma
22 120627 18 2900000 7200000 Amplification Cutaneous T-cell lymphoma
23 123359 18 71300000 76117153 Deletion PARD6G Cutaneous T-cell lymphoma
24 133686 19 6900000 12600000 Deletion Cutaneous T-cell lymphoma
25 142291 2 221300000 224900000 Deletion Cutaneous T-cell lymphoma
26 152036 20 28400000 31500000 Amplification BCL2L1 Cutaneous T-cell lymphoma
27 162458 22 21800000 24300000 Amplification Cutaneous T-cell lymphoma
28 162461 22 21800000 24300000 Deletion Cutaneous T-cell lymphoma
29 171538 3 169200000 172500000 Amplification PRKCI Cutaneous T-cell lymphoma
30 180261 4 102500000 107900000 Amplification Cutaneous T-cell lymphoma
31 180582 4 107900000 114100000 Amplification Cutaneous T-cell lymphoma
32 181002 4 114100000 120600000 Amplification Cutaneous T-cell lymphoma
33 184833 4 182600000 187300000 Deletion Cutaneous T-cell lymphoma
34 186902 4 40900000 45600000 Deletion Cutaneous T-cell lymphoma
35 190065 4 82600000 84300000 Deletion Cutaneous T-cell lymphoma
36 203973 6 104800000 113900000 Deletion Cutaneous T-cell lymphoma
37 206027 6 135200000 139100000 Deletion Cutaneous T-cell lymphoma
38 211016 6 31900000 33600000 Deletion Cutaneous T-cell lymphoma
39 212690 6 40600000 45200000 Deletion VEGFA Cutaneous T-cell lymphoma
40 222425 7 15200000 19500000 Deletion Cutaneous T-cell lymphoma
41 225996 7 53900000 57400000 Amplification EGFR Cutaneous T-cell lymphoma
42 233736 8 127300000 131500000 Amplification MYC Cutaneous T-cell lymphoma
43 237881 8 27400000 29700000 Deletion Cutaneous T-cell lymphoma
44 238080 8 29700000 38500000 Deletion Cutaneous T-cell lymphoma
45 239603 8 39900000 43200000 Deletion Cutaneous T-cell lymphoma
46 243701 8 87200000 93500000 Amplification Cutaneous T-cell lymphoma
47 244139 8 93500000 99100000 Deletion Cutaneous T-cell lymphoma
48 249980 9 19900000 25500000 Deletion CDKN2A Cutaneous T-cell lymphoma
49 255727 9 83400000 86100000 Deletion Cutaneous T-cell lymphoma

Expression for Cutaneous T Cell Lymphoma

Search GEO for disease gene expression data for Cutaneous T Cell Lymphoma.

Pathways for Cutaneous T Cell Lymphoma

Pathways related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 CCR10 CCR4 HDAC9 IFNA1 IFNG IL15
2
Show member pathways
13.3 CCR10 CCR4 IL15 IL2 IL2RA IL7
3
Show member pathways
13.25 IFNA1 IFNG IL15 IL2 IL2RA IL7
4
Show member pathways
13.19 CCR10 CCR4 IL15 IL2 IL2RA IL7
5 12.73 IFNA1 IFNG IL15 IL2 IL2RA IL7
6
Show member pathways
12.72 CCR10 GZMB IFNA1 IFNG IL15 IL2
7
Show member pathways
12.39 GZMB IFNA1 IFNG IL2
8 12.36 GZMB IFNA1 IFNG IL2 IL2RA TNFRSF8
9
Show member pathways
12.16 IFNA1 IFNG IL15 IL2 IL2RA
10
Show member pathways
12.16 IFNA1 IFNG IL15 IL2 IL2RA IL7
11
Show member pathways
11.98 IFNG IL15 IL2 IL2RA IL7
12
Show member pathways
11.83 GZMB IFNG IL2 IL2RA
13
Show member pathways
11.65 IFNG IL2 IL2RA
14 11.62 IFNG IL15 IL2 IL2RA IL7
15 11.61 IFNG IL15 IL2
16 11.6 IFNA1 IFNG IL15 IL2 IL2RA
17
Show member pathways
11.49 GZMB IFNG IL2 IL2RA
18 11.4 IFNG IL2 IL2RA
19 11.23 IFNG IL2 IL2RA
20 11.19 IFNG IL15 IL7
21 11.08 IFNG IL2 IL2RA
22 11 GZMB IFNG IL15 IL2 IL2RA IL7
23 10.72 IFNG IL15 IL2 IL7

GO Terms for Cutaneous T Cell Lymphoma

Cellular components related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum exit site GO:0070971 8.8 CTAGE1 CTAGE4 MIA2

Biological processes related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.91 IFNA1 IFNG IL15 IL2 IL7
2 cytokine-mediated signaling pathway GO:0019221 9.86 IFNA1 IL2 IL2RA IL7
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 IFNG IL15 IL2
4 positive regulation of T cell proliferation GO:0042102 9.67 IL15 IL2 IL2RA
5 humoral immune response GO:0006959 9.65 IFNA1 IFNG IL7
6 protein secretion GO:0009306 9.58 CTAGE1 CTAGE4 MIA2
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.57 IFNA1 IFNG
8 positive regulation of interleukin-17 production GO:0032740 9.55 IL15 IL2
9 interleukin-2-mediated signaling pathway GO:0038110 9.54 IL2 IL2RA
10 lipoprotein transport GO:0042953 9.5 CTAGE1 CTAGE4 MIA2
11 negative regulation of lymphocyte proliferation GO:0050672 9.46 IL2 IL2RA
12 positive regulation of tissue remodeling GO:0034105 9.43 IL15 IL2
13 positive regulation of T cell differentiation GO:0045582 9.43 IL2 IL2RA IL7
14 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2 IL2RA
15 regulation of regulatory T cell differentiation GO:0045589 9.33 IFNG IL2 IL2RA
16 immune response GO:0006955 9.17 CCR10 CCR4 IFNG IL15 IL2 IL2RA
17 cargo loading into vesicle GO:0035459 9.13 CTAGE1 CTAGE4 MIA2

Molecular functions related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 IFNA1 IFNG IL15 IL2 IL7
2 cytokine receptor binding GO:0005126 9.33 IFNA1 IL15 IL7
3 lipoprotein transporter activity GO:0042954 8.8 CTAGE1 CTAGE4 MIA2

Sources for Cutaneous T Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....